WWW.BOOK.DISLIB.INFO
FREE ELECTRONIC LIBRARY - Books, dissertations, abstract
 
<< HOME
CONTACTS



Pages:     | 1 |   ...   | 3 | 4 || 6 | 7 |   ...   | 34 |

«2013 Annual Report breakthrough technologies and services focused on Dear Fellow Shareholders, addressing specific customer and market needs. Several ...»

-- [ Page 5 ] --

Our customers include pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors and government agencies. Our quarterly revenue and results of operations are highly dependent on the volume and timing of orders received during the quarter. In addition, our revenues and earnings forecasts for future quarters are often based on the expected trends in our markets. However, the markets we serve do not always experience the trends that we may expect. Negative fluctuations in our customers’ markets, the inability of our customers to secure credit or funding, restrictions in capital expenditures, general economic conditions, cuts in government funding or unfavorable changes in government regulations would likely result in a reduction in demand for our products and services. In addition, government funding is subject to economic conditions and the political process, which is inherently fluid and unpredictable. Our revenues may be adversely affected if our customers delay or reduce purchases as a result of uncertainties surrounding the approval of government or industrial funding proposals.

Such declines could harm our consolidated financial position, results of operations, cash flows and trading price of our common stock, and could limit our ability to sustain profitability.

Our growth is subject to global economic and political conditions, and operational disruptions at our facilities.

Our business is affected by global economic conditions and the state of the financial markets, particularly as the United States and other countries balance concerns around debt, inflation, growth and budget allocations in their policy initiatives. There can be no assurance that global economic conditions and financial markets will not worsen and that we will not experience any adverse effects that may be material to our consolidated cash flows, results of operations, financial position or our ability to access capital, such as the adverse effects resulting from a prolonged shutdown in government operations both in the United States and internationally. Our business is also affected by local economic environments, including inflation, recession, financial liquidity and currency volatility or devaluation. Political changes, some of which may be disruptive, could interfere with our supply chain, our customers and all of our activities in a particular location.

While we take precautions to prevent production or service interruptions at our global facilities, a major earthquake, fire, flood, power loss or other catastrophic event that results in the destruction or delay of any of our critical business operations could result in our incurring significant liability to customers or other third parties, cause significant reputational damage or have a material adverse effect on our business, operating results or financial condition.

Certain of these risks can be hedged to a limited degree using financial instruments, or other measures, and some of these risks are insurable, but any such mitigation efforts are costly and may not always be fully successful. Our ability to engage in such mitigation efforts has decreased or become even more costly as a result of recent market developments.

If we do not introduce new products in a timely manner, we may lose market share and be unable to achieve revenue growth targets.

We sell many of our products in industries characterized by rapid technological change, frequent new product and service introductions, and evolving customer needs and industry standards. Many of the businesses competing with us in these industries have significant financial and other resources to invest in new technologies, substantial intellectual property portfolios, substantial experience in new product development, regulatory expertise, manufacturing capabilities, and established distribution channels to deliver products to customers. Our products could become technologically obsolete over time, or we may invest in technology that does not lead to revenue growth or continue to sell products for which the demand from our customers is declining, in which case we may lose market share or not achieve our revenue growth targets. The success of our new product offerings

will depend upon several factors, including our ability to:

• accurately anticipate customer needs,

• innovate and develop new technologies and applications,

• successfully commercialize new technologies in a timely manner,

• price our products competitively, and manufacture and deliver our products in sufficient volumes and on time, and

• differentiate our offerings from our competitors’ offerings.

Many of our products are used by our customers to develop, test and manufacture their products. We must anticipate industry trends and consistently develop new products to meet our customers’ expectations. In developing new products, we may be required to make significant investments before we can determine the commercial viability of the new product. If we fail to accurately foresee our customers’ needs and future activities, we may invest heavily in research and development of products that do not lead to significant revenue.

We may also suffer a loss in market share and potential revenue if we are unable to commercialize our technology in a timely and efficient manner.





In addition, some of our licensed technology is subject to contractual restrictions, which may limit our ability to develop or commercialize products for some applications.

We may not be able to successfully execute acquisitions or license technologies, integrate acquired businesses or licensed technologies into our existing businesses, make acquired businesses or licensed technologies profitable, or successfully divest businesses.

We have in the past supplemented, and may in the future supplement, our internal growth by acquiring businesses and licensing technologies that complement or augment our existing product lines, such as our acquisition of Shanghai Haoyuan Biotech Co., Ltd. (“Haoyuan”) in the fourth quarter of fiscal year 2012.

However, we may be unable to identify or complete promising acquisitions or license transactions for many

reasons, such as:

• competition among buyers and licensees,

• the high valuations of businesses and technologies,

• the need for regulatory and other approval, and

• our inability to raise capital to fund these acquisitions.

Some of the businesses we acquire may be unprofitable or marginally profitable, or may increase the variability of our revenue recognition. Accordingly, the earnings or losses of acquired businesses may dilute our earnings. For these acquired businesses to achieve acceptable levels of profitability, we would have to improve their management, operations, products and market penetration. We may not be successful in this regard and may encounter other difficulties in integrating acquired businesses into our existing operations, such as incompatible management, information or other systems, cultural differences, loss of key personnel, unforeseen regulatory requirements, previously undisclosed liabilities or difficulties in predicting financial results. Additionally, if we are not successful in selling businesses we seek to divest, the activity of such businesses may dilute our earnings and we may not be able to achieve the expected benefits of such divestitures. As a result, our financial results may differ from our forecasts or the expectations of the investment community in a given quarter or over the long term.

To finance our acquisitions, we may have to raise additional funds, either through public or private financings. We may be unable to obtain such funds or may be able to do so only on terms unacceptable to us. We may also incur expenses related to completing acquisitions or licensing technologies, or in evaluating potential acquisitions or technologies, which may adversely impact our profitability.

We may not be successful in adequately protecting our intellectual property.

Patent and trade secret protection is important to us because developing new products, processes and technologies gives us a competitive advantage, although it is time-consuming and expensive. We own many United States and foreign patents and intend to apply for additional patents. Patent applications we file, however, may not result in issued patents or, if they do, the claims allowed in the patents may be narrower than what is needed to protect fully our products, processes and technologies. The expiration of our previously issued patents may cause us to lose a competitive advantage in certain of the products and services we provide. Similarly, applications to register our trademarks may not be granted in all countries in which they are filed. For our intellectual property that is protected by keeping it secret, such as trade secrets and know-how, we may not use adequate measures to protect this intellectual property.

Third parties may also challenge the validity of our issued patents, may circumvent or “design around” our patents and patent applications, or may claim that our products, processes or technologies infringe their patents.

In addition, third parties may assert that our product names infringe their trademarks. We may incur significant expense in legal proceedings to protect our intellectual property against infringement by third parties or to defend against claims of infringement by third parties. Claims by third parties in pending or future lawsuits could result in awards of substantial damages against us or court orders that could effectively prevent us from manufacturing, using, importing or selling our products in the United States or other countries.

If we are unable to renew our licenses or otherwise lose our licensed rights, we may have to stop selling products or we may lose competitive advantage.

We may not be able to renew our existing licenses, or licenses we may obtain in the future, on terms acceptable to us, or at all. If we lose the rights to a patented or other proprietary technology, we may need to stop selling products incorporating that technology and possibly other products, redesign our products or lose a competitive advantage. Potential competitors could in-license technologies that we fail to license and potentially erode our market share.

Our licenses typically subject us to various economic and commercialization obligations. If we fail to comply with these obligations, we could lose important rights under a license, such as the right to exclusivity in a market. In some cases, we could lose all rights under the license. In addition, rights granted under the license could be lost for reasons out of our control. For example, the licensor could lose patent protection for a number of reasons, including invalidity of the licensed patent, or a third-party could obtain a patent that curtails our freedom to operate under one or more licenses.

If we do not compete effectively, our business will be harmed.

We encounter aggressive competition from numerous competitors in many areas of our business. We may not be able to compete effectively with all of these competitors. To remain competitive, we must develop new products and periodically enhance our existing products. We anticipate that we may also have to adjust the prices of many of our products to stay competitive. In addition, new competitors, technologies or market trends may emerge to threaten or reduce the value of entire product lines.

Our quarterly operating results could be subject to significant fluctuation, and we may not be able to adjust our operations to effectively address changes we do not anticipate, which could increase the volatility of our stock price and potentially cause losses to our shareholders.

Given the nature of the markets in which we participate, we cannot reliably predict future revenue and profitability. Changes in competitive, market and economic conditions may require us to adjust our operations, and we may not be able to make those adjustments or make them quickly enough to adapt to changing conditions. A high proportion of our costs are fixed, due in part to our research and development and manufacturing costs. As a result, small declines in sales could disproportionately affect our operating results in a

quarter. Factors that may affect our quarterly operating results include:

• demand for and market acceptance of our products,

• competitive pressures resulting in lower selling prices,



Pages:     | 1 |   ...   | 3 | 4 || 6 | 7 |   ...   | 34 |


Similar works:

«Annual Review of Drinking-Water Quality In New Zealand 2007/8 Citation: Ministry of Health. 2008. Annual Review of Drinking-Water Quality in New Zealand 2007/8. Wellington: Ministry of Health. Published by the Ministry of Health in October 2009 PO Box 5013, Wellington, New Zealand ISSN 1176-1424 (Print) ISSN 1179-2604 (Online) HP 4958 This document is available on the Ministry of Health’s website: http:// www.moh.govt.nz/water Ministry of Health Disclaimer The data and analyses contained in...»

«Under the Factories and Industrial Undertakings (Safety Officers and Safety Supervisors) Regulations Application 1. Application for registration as a safety officer under the Factories and Industrial Undertakings (Safety Officers and Safety Supervisors) Regulations shall be made in a prescribed application form FORM 1.2. The prescribed application forms are downloadable from the Labour Department’s homepage (http://www.labour.gov.hk/) and obtainable free of charge from every branch office of...»

«Chronic stress during the peripartum period: Implications for mother and offspring DISSERTATION ZUR ERLANGUNG DES DOKTORGRADES DER NATURWISSENSCHAFTEN (DR. RER. NAT.) DER FAKULTÄT FÜR BIOLOGIE UND VORKLINISCHEN MEDIZIN DER UNIVERSITÄT REGENSBURG vorgelegt von Katharina Hillerer aus Passau im Jahr 2011 Das Promotionsgesuch wurde eingereicht am: 18.11.2011 Die Arbeit wurde angeleitet von Prof. Dr. Inga D. Neumann Unterschrift: Prologue “At first I thought what I was feeling was just...»

«WorkCover NSW guide for accreditation of assessors for high risk work licences Includes application for: New accreditation Accreditation in additional classes Renewal of accreditation Mutual recognition of assessor accreditation May 2015 Disclaimer This publication may contain work health and safety and workers compensation information. It may include some of your obligations under the various legislations that WorkCover NSW administers. To ensure you comply with your legal obligations you must...»

«2015 / 2 Annotierte Online–Bibliografie Thomas Siebold, Heike Watermülder Global Health Governance: Gesundheit als globales Politikfeld Global Health Governance: Health as a global policy area 16. März 2015 Herausgeber: GIGA German Institute of Global and Area Studies / Leibniz-Institut für Globale und Regionale Studien GIGA Informationszentrum Neuer Jungfernstieg 21 20354 Hamburg Tel.: +49 (0) 40 42825 598 Fax: +49 (0) 40 42825 512 E-Mail: iz@giga-hamburg.de Web: http://giga-hamburg.de/iz...»

«HIV-spezifische DNA-Impfstoffe mit verbessertem Sicherheitsund Wirksamkeitsprofil: Grundlage innovativer Vakzinestrategien DISSERTATION ZUR ERLANGUNG DES DOKTORGRADES DER NATURWISSENSCHAFTEN (DR.RER.NAT.) DER NATURWISSENSCHAFTLICHEN FAKULTÄT III -BIOLOGIE UND VORKLINISCHE MEDIZINDER UNIVERSITÄT REGENSBURG vorgelegt von Kurt Bieler aus Weiden Mai 2002 Die vorliegende Dissertation wurde zwischen März 1998 und Mai 2002 am Institut für Medizinische Mikrobiologie und Hygiene an der Universität...»

«THE LAW AND ETHICS OF USING THE DEAD IN RESEARCH BY CATHERINE M. HAMMACK A Thesis Submitted to the Graduate Faculty of WAKE FOREST UNIVERSITY GRADUATE SCHOOL OF ARTS AND SCIENCES in Partial Fulfillment of the Requirements for the Degree of MASTER OF ARTS Bioethics December, 2014 Winston-Salem, North Carolina Approved By: Christine N. Coughlin, JD, Advisor Nancy King, JD, Chair Tanya Marsh, JD ACKNOWLEDGMENTS Thank you to everyone at the Center for Bioethics, Health and Society and the Master of...»

«Chapter 2 Animal Health Markets and Opportunities: Companion Animal Landscape Linda J.I. Horspool Abstract In the future, the global market for companion animal health products is expected to further grow and become more specialized. The major drivers will be the continued strengthening of the bond between owners and their animal companions, increasing companion animal owner awareness, and increasing companion animal owner demands and expectations for companion animal care. This chapter...»

«Curriculum Vitae DR. MED. JÜRGEN J. WENZEL Institut für Klinische Mikrobiologie und Hygiene Universitätsklinikum Regensburg Franz-Josef-Strauß-Allee 11 93053 Regensburg Juergen.Wenzel@ukr.de Studium und Medizinische Ausbildung 1998 – 2005 Medizinstudium an der Universität Regensburg 2005 – 2006 Assistenzarzt Kardiologie, Johannes Gutenberg-Universität Mainz 2006 – 2007 Assistenzarzt Laboratoriumsmedizin, Johannes Gutenberg-Universität Mainz 2007 – 2012 Assistenzarzt am Institut...»

«Assistance and Technical Work in the Medical, Hospital, Dental, & Public Health Group, GS-0600 May 2001 Job Family Position Classification Standard for Assistance and Technical Work in the Medical, Hospital, Dental, and Public Health Group, GS-0600 Table of Contents INTRODUCTION COVERAGE MODIFICATIONS TO AND CANCELLATIONS OF OTHER EXISTING OCCUPATIONAL SERIES AND STANDARDS GENERAL SERIES, TITLING, AND OCCUPATIONAL GUIDANCE GENERAL TITLING PROVISIONS INFORMATION BY SERIES MEDICAL RECORDS...»





 
<<  HOME   |    CONTACTS
2016 www.book.dislib.info - Free e-library - Books, dissertations, abstract

Materials of this site are available for review, all rights belong to their respective owners.
If you do not agree with the fact that your material is placed on this site, please, email us, we will within 1-2 business days delete him.